You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

second line

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relevance and Efficiency of SecOnd Line Workup for Uveitis

Not yet recruiting
  • Uveitis
  • second line investigations for uveitis etiological workup
  • (no location specified)
Oct 25, 2023

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)

Not yet recruiting
  • Second Line Treatment of Gastric Cancer
  • (no location specified)
Dec 20, 2022

GBM Trial (Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields))

Not yet recruiting
  • GBM
  • (no location specified)
Aug 2, 2023

Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)

Recruiting
  • Cervical Cancer Recurrent
  • RC48 + Tislelizumab
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 25, 2023

Mesotheliomas Pleural Trial in Amsterdam (Pembrolizumab, Lenvatinib)

Recruiting
  • Mesotheliomas Pleural
  • Amsterdam, Noord-Holland, Netherlands
    Antoni van Leeuwenhoekziekenhuis (NKI-AVL)
Jan 13, 2023

HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

Recruiting
  • HER2-positive Gastric Cancer
  • Immunotherapy
  • Disitamab Vedotin combined with fruquintinib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2023

Cholangiocarcinoma Trial (Carrelizumab, Solfantinib)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Jan 16, 2023

Colorectal Cancer Trial in Changsha (fruquintinib and FOLFIRI)

Not yet recruiting
  • Colorectal Cancer
  • fruquintinib and FOLFIRI
  • Changsha, Hunan, China
    Hunan Cancer hospital
Apr 24, 2023

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Gastric / Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (envafolimab and lenvatinib combined with

Enrolling by invitation
  • Gastric / Gastroesophageal Junction Adenocarcinoma
  • envafolimab and lenvatinib combined with paclitaxel-albumin
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Sep 3, 2023

Metastatic Gastric Adenocarcinoma, Second Line, Chemo Trial (nal-IRI /Experimental, Ramucirumab /Experimental,

Not yet recruiting
  • Metastatic Gastric Adenocarcinoma
  • +2 more
  • nal-IRI /Experimental
  • +2 more
  • (no location specified)
Jun 25, 2023

Pancreatic Tumors Trial (Tislelizumab)

Not yet recruiting
  • Pancreatic Neoplasms
  • (no location specified)
Dec 26, 2022

Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Apatinib Mesylate
  • Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Mar 1, 2023

Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)

Recruiting
  • Immunotherapy
  • Second-line Treatment
  • Guizhou, ZunYi, China
    The Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023

Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Nov 27, 2022

Progression-free Survival Trial (Sovalteinib Solutumab Tegeo)

Not yet recruiting
  • Progression-free Survival
  • Sovalteinib Solutumab Tegeo
  • (no location specified)
Jul 24, 2023

Intrahepatic Cholangiocarcinoma Trial in Tianjin (Regorafenib and HAIC, FOLFOX)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Sep 7, 2022

HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • trastuzumab, bevacizumab with paclitaxel (triple combination)
  • (no location specified)
Dec 6, 2022

Metastatic Pancreatic Adenocarcinoma Trial (Avelumab and Pepinemab)

Recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • Avelumab and Pepinemab
  • Rochester, New York
    University of Rochester Medical Center
Jan 19, 2023

Stomach Tumors Trial in Wuhan (Fruquintinib, Sintilimab)

Not yet recruiting
  • Stomach Neoplasms
  • Wuhan, Hubei, China
    Wuhan Union Hospital, China
Nov 22, 2022

Adrenocortical Carcinoma Trial (Camrelizumab)

Recruiting
  • Adrenocortical Carcinoma
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Dec 16, 2022

Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)

Not yet recruiting
  • Recurrent Liver Cancer After Liver Transplantation
  • Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
  • (no location specified)
Apr 17, 2023

Smoking Cessation, Harm Reduction Trial in Charlotte, Raleigh (Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product)

Not yet recruiting
  • Smoking Cessation
  • Harm Reduction
  • Charlotte, North Carolina
  • +1 more
Oct 17, 2023

Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2023